# Elanco Animal Health Inc: financial statements, quarterly

ELAN · NYSE · CIK 1739104 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/elan.md) · [Financials](/companies/elan/financials.md) · [Filings](/companies/elan/filings.md) · [Insiders](/companies/elan/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/elan/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,068](/filings/0001739104-24-000039.md) | [1,035 d](/filings/0001739104-26-000012.md) | [1,205](/filings/0001739104-25-000042.md) | [1,184](/filings/0001739104-25-000055.md) | [1,030](/filings/0001739104-25-000071.md) | [1,020 d](/filings/0001739104-26-000012.md) | [1,193](/filings/0001739104-26-000030.md) | [1,241](/filings/0001739104-26-000043.md) | [1,137](/filings/0001739104-25-000071.md) | [1,144 d](/filings/0001739104-26-000012.md) | [1,371](/filings/0001739104-26-000030.md) | [1,368](/filings/0001739104-26-000043.md) |
| Cost of revenue | $m | [487](/filings/0001739104-24-000039.md) | [516 d](/filings/0001739104-26-000012.md) | [515](/filings/0001739104-25-000042.md) | [495](/filings/0001739104-25-000055.md) | [492](/filings/0001739104-25-000071.md) | [501 d](/filings/0001739104-26-000012.md) | [509](/filings/0001739104-26-000030.md) | [528](/filings/0001739104-26-000043.md) | [530](/filings/0001739104-25-000071.md) | [555 d](/filings/0001739104-26-000012.md) | [586](/filings/0001739104-26-000030.md) | [570](/filings/0001739104-26-000043.md) |
| Gross profit | $m | not reported | not reported | [690](/filings/0001739104-25-000042.md) | [689](/filings/0001739104-25-000055.md) | [538](/filings/0001739104-25-000071.md) | [519 d](/filings/0001739104-26-000012.md) | [684](/filings/0001739104-26-000030.md) | [713](/filings/0001739104-26-000043.md) | [607](/filings/0001739104-25-000071.md) | [589 d](/filings/0001739104-26-000012.md) | [785](/filings/0001739104-26-000030.md) | [798](/filings/0001739104-26-000043.md) |
| Research and development | $m | [86.0](/filings/0001739104-24-000039.md) | [79.0 d](/filings/0001739104-26-000012.md) | [87.0](/filings/0001739104-25-000042.md) | [89.0](/filings/0001739104-25-000055.md) | [87.0](/filings/0001739104-25-000071.md) | [81.0 d](/filings/0001739104-26-000012.md) | [94.0](/filings/0001739104-26-000030.md) | [92.0](/filings/0001739104-26-000043.md) | [89.0](/filings/0001739104-25-000071.md) | [93.0 d](/filings/0001739104-26-000012.md) | [97.0](/filings/0001739104-26-000030.md) | [92.0](/filings/0001739104-26-000043.md) |
| Selling, general and administrative | $m | [313](/filings/0001739104-24-000039.md) | [292 d](/filings/0001739104-26-000012.md) | [337](/filings/0001739104-25-000042.md) | [354](/filings/0001739104-25-000055.md) | [323](/filings/0001739104-25-000071.md) | [300 d](/filings/0001739104-26-000012.md) | [341](/filings/0001739104-26-000030.md) | [400](/filings/0001739104-26-000043.md) | [351](/filings/0001739104-25-000071.md) | [338 d](/filings/0001739104-26-000012.md) | [381](/filings/0001739104-26-000030.md) | [449](/filings/0001739104-26-000043.md) |
| Interest expense | $m | [72.0](/filings/0001739104-24-000039.md) | [67.0 d](/filings/0001739104-24-000009.md) | [66.0](/filings/0001739104-24-000018.md) | [65.0](/filings/0001739104-24-000027.md) | [58.0](/filings/0001739104-24-000039.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(1.0)](/filings/0001739104-24-000039.md) | [14.0 d](/filings/0001739104-26-000012.md) | [(20.0)](/filings/0001739104-25-000042.md) | [18.0](/filings/0001739104-25-000055.md) | [195](/filings/0001739104-25-000071.md) | [(43.0) d](/filings/0001739104-26-000012.md) | [(7.0)](/filings/0001739104-26-000030.md) | [14.0](/filings/0001739104-26-000043.md) | [(16.0)](/filings/0001739104-25-000071.md) | [17.0 d](/filings/0001739104-26-000012.md) | [30.0](/filings/0001739104-26-000030.md) | [2.0](/filings/0001739104-26-000043.md) |
| Net income | $m | [(1,096)](/filings/0001739104-24-000039.md) | [(141) d](/filings/0001739104-26-000012.md) | [32.0](/filings/0001739104-25-000071.md) | [(50.0)](/filings/0001739104-25-000071.md) | [364](/filings/0001739104-25-000071.md) | [(8.0) d](/filings/0001739104-26-000012.md) | [67.0](/filings/0001739104-26-000043.md) | [11.0](/filings/0001739104-26-000043.md) | [(34.0)](/filings/0001739104-25-000071.md) | [(276) d](/filings/0001739104-26-000012.md) | [57.0](/filings/0001739104-26-000043.md) | [54.0](/filings/0001739104-26-000043.md) |
| Diluted EPS | $ per share | [(2.22)](/filings/0001739104-24-000039.md) | not reported | [0.06](/filings/0001739104-25-000042.md) | [(0.10)](/filings/0001739104-25-000055.md) | [0.73](/filings/0001739104-25-000071.md) | not reported | [0.13](/filings/0001739104-26-000030.md) | [0.02](/filings/0001739104-26-000043.md) | [(0.07)](/filings/0001739104-25-000071.md) | not reported | [0.11](/filings/0001739104-26-000030.md) | [0.11](/filings/0001739104-26-000043.md) |
| Basic EPS | $ per share | [(2.22)](/filings/0001739104-24-000039.md) | not reported | [0.06](/filings/0001739104-25-000042.md) | [(0.10)](/filings/0001739104-25-000055.md) | [0.74](/filings/0001739104-25-000071.md) | not reported | [0.14](/filings/0001739104-26-000030.md) | [0.02](/filings/0001739104-26-000043.md) | [(0.07)](/filings/0001739104-25-000071.md) | not reported | [0.11](/filings/0001739104-26-000030.md) | [0.11](/filings/0001739104-26-000043.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.4](/filings/0001739104-23-000023.md) | [0.4](/filings/0001739104-25-000014.md) | [0.3](/filings/0001739104-24-000018.md) | [0.4](/filings/0001739104-24-000027.md) | [0.5](/filings/0001739104-24-000039.md) | [0.5](/filings/0001739104-26-000012.md) | [0.5](/filings/0001739104-25-000042.md) | [0.5](/filings/0001739104-25-000055.md) | [0.5](/filings/0001739104-25-000071.md) | [0.5](/filings/0001739104-26-000043.md) | [0.4](/filings/0001739104-26-000030.md) | [0.5](/filings/0001739104-26-000043.md) |
| Current assets | $bn | [3.6](/filings/0001739104-23-000023.md) | [3.4](/filings/0001739104-25-000014.md) | [4.1](/filings/0001739104-24-000018.md) | [4.0](/filings/0001739104-24-000027.md) | [3.4](/filings/0001739104-24-000039.md) | [3.2](/filings/0001739104-26-000012.md) | [3.4](/filings/0001739104-25-000042.md) | [3.6](/filings/0001739104-25-000055.md) | [3.5](/filings/0001739104-25-000071.md) | [3.5](/filings/0001739104-26-000043.md) | [3.6](/filings/0001739104-26-000030.md) | [3.8](/filings/0001739104-26-000043.md) |
| Total assets | $bn | [14.3](/filings/0001739104-23-000023.md) | [14.4](/filings/0001739104-25-000014.md) | [14.0](/filings/0001739104-24-000018.md) | [13.8](/filings/0001739104-24-000027.md) | [13.3](/filings/0001739104-24-000039.md) | [12.6](/filings/0001739104-26-000012.md) | [12.9](/filings/0001739104-25-000042.md) | [13.7](/filings/0001739104-25-000055.md) | [13.6](/filings/0001739104-25-000071.md) | [13.4](/filings/0001739104-26-000043.md) | [13.2](/filings/0001739104-26-000030.md) | [13.6](/filings/0001739104-26-000043.md) |
| Current liabilities | $bn | [1.3](/filings/0001739104-23-000023.md) | [1.2](/filings/0001739104-25-000014.md) | [1.2](/filings/0001739104-24-000018.md) | [1.4](/filings/0001739104-24-000027.md) | [1.3](/filings/0001739104-24-000039.md) | [1.3](/filings/0001739104-26-000012.md) | [1.3](/filings/0001739104-25-000042.md) | [1.4](/filings/0001739104-25-000055.md) | [1.5](/filings/0001739104-25-000071.md) | [1.6](/filings/0001739104-26-000043.md) | [1.7](/filings/0001739104-26-000030.md) | [1.9](/filings/0001739104-26-000043.md) |
| Total liabilities | $bn | [8.2](/filings/0001739104-23-000023.md) | [8.1](/filings/0001739104-25-000014.md) | [8.0](/filings/0001739104-24-000018.md) | [7.8](/filings/0001739104-24-000027.md) | [6.8](/filings/0001739104-24-000039.md) | [6.5](/filings/0001739104-26-000012.md) | [6.6](/filings/0001739104-25-000042.md) | [7.0](/filings/0001739104-25-000055.md) | [6.8](/filings/0001739104-25-000071.md) | [6.8](/filings/0001739104-26-000043.md) | [6.7](/filings/0001739104-26-000030.md) | [7.0](/filings/0001739104-26-000043.md) |
| Long-term debt | $bn | [5.9](/filings/0001739104-23-000023.md) | [5.7](/filings/0001739104-25-000014.md) | [5.7](/filings/0001739104-24-000018.md) | [5.5](/filings/0001739104-24-000027.md) | [4.3](/filings/0001739104-24-000039.md) | [4.3](/filings/0001739104-25-000042.md) | [4.4](/filings/0001739104-25-000042.md) | [4.0](/filings/0001739104-25-000055.md) | [3.8](/filings/0001739104-25-000071.md) | [3.8](/filings/0001739104-26-000043.md) | [3.7](/filings/0001739104-26-000030.md) | [3.7](/filings/0001739104-26-000043.md) |
| Current portion of debt | $bn | [0.0](/filings/0001739104-23-000023.md) | [0.0](/filings/0001739104-25-000014.md) | [0.0](/filings/0001739104-24-000018.md) | [0.2](/filings/0001739104-24-000027.md) | [0.0](/filings/0001739104-24-000039.md) | [0.0](/filings/0001739104-25-000042.md) | [0.0](/filings/0001739104-25-000042.md) | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [6.1](/filings/0001739104-24-000039.md) | [6.2](/filings/0001739104-26-000012.md) | [6.1](/filings/0001739104-25-000071.md) | [5.9](/filings/0001739104-25-000071.md) | [6.5](/filings/0001739104-25-000071.md) | [6.1](/filings/0001739104-26-000043.md) | [6.4](/filings/0001739104-26-000043.md) | [6.8](/filings/0001739104-26-000043.md) | [6.7](/filings/0001739104-25-000071.md) | [6.5](/filings/0001739104-26-000043.md) | [6.5](/filings/0001739104-26-000043.md) | [6.6](/filings/0001739104-26-000043.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [198 d](/filings/0001739104-24-000039.md) | [157 d](/filings/0001739104-26-000012.md) | [2.0](/filings/0001739104-25-000042.md) | [200 d](/filings/0001739104-25-000055.md) | [162 d](/filings/0001739104-25-000071.md) | [177 d](/filings/0001739104-26-000012.md) | [(4.0)](/filings/0001739104-26-000030.md) | [237 d](/filings/0001739104-26-000043.md) | [219 d](/filings/0001739104-25-000071.md) | [108 d](/filings/0001739104-26-000012.md) | [13.0](/filings/0001739104-26-000030.md) | [277 d](/filings/0001739104-26-000043.md) |
| Capital expenditure | $m | [33.0 d](/filings/0001739104-24-000039.md) | [41.0 d](/filings/0001739104-26-000012.md) | [24.0](/filings/0001739104-25-000042.md) | [34.0 d](/filings/0001739104-25-000055.md) | [42.0 d](/filings/0001739104-25-000071.md) | [47.0 d](/filings/0001739104-26-000012.md) | [65.0](/filings/0001739104-26-000030.md) | [57.0 d](/filings/0001739104-26-000043.md) | [92.0 d](/filings/0001739104-25-000071.md) | [62.0 d](/filings/0001739104-26-000012.md) | [51.0](/filings/0001739104-26-000030.md) | [33.0 d](/filings/0001739104-26-000043.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [488](/filings/0001739104-23-000023.md) | [493](/filings/0001739104-24-000018.md) | [493](/filings/0001739104-24-000027.md) | [493](/filings/0001739104-24-000039.md) | [496](/filings/0001739104-25-000042.md) | [494](/filings/0001739104-25-000055.md) | [498](/filings/0001739104-25-000071.md) | [499](/filings/0001739104-26-000030.md) | [500](/filings/0001739104-26-000043.md) | [497](/filings/0001739104-25-000071.md) | [506](/filings/0001739104-26-000030.md) | [506](/filings/0001739104-26-000043.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 499,621,830 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001739104-26-000043.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.